

TRULIGN[®]
POSTERIOR CHAMBER INTRAOCULAR LENS **TORIC**

Bringing **astigmatism**
AND presbyopia
into focus.



LONG TERM VISION | FOR YOUR PATIENTS | FOR YOUR PRACTICE

BAUSCH + LOMB

From here on out, it's TRULIGN®

Treat astigmatic cataract patients and provide a natural range of vision.

Designed to comfortably fit your patients' lifestyles, TRULIGN Toric IOL corrects astigmatism and presbyopia while offering a broad range of vision for everyday activities like using a computer, driving, hobbies and crafts, and socializing.¹

High quality and high quantity vision, all in one.

TRULIGN provides not only sharp, clear vision for patients but extraordinary rotational stability, excellent astigmatism correction, outstanding refractive predictability, and effective centration.² Count on TRULIGN to deliver astigmatic cataract correction with intermediate and distance vision in a single surgery.

Excellent Intermediate and Distance Vision Results²

	Uncorrected intermediate visual acuity	Uncorrected distance visual acuity
≥ 20/25 ▶	86.6%	72.4%
≥ 20/32 ▶	94.1%	86.6%
≥ 20/40 ▶	97.8%	97.8%



Make the difference of a lifetime with TRULIGN Toric IOL.

"For my astigmatic patients looking for an active lifestyle, including both intermediate and distance vision, I recommend the TRULIGN Toric IOL. This lens offers a broader range of vision than any standard toric IOL, which satisfies the patients' need for enhancing overall vision and regaining an active lifestyle."

– Mitchell A. Jackson, MD



Proven stability for predictable results.

The standard for astigmatism correction.

A prospective multicenter clinical trial (N=229) shows that TRULIGN provides an extremely high level of **rotational stability** and offers:

- Rotation of $\leq 5^\circ$ in 96.1% of eyes²
- Excellent centration²
 - 0.007 mm mean total decentration
- Outstanding refractive predictability²
 - MRSE ≤ 0.5 D for 78% of eyes
 - MRSE ≤ 1.0 D for 95% of eyes



Mean Rotation $\leq 5^\circ$
at Six Months²



Residual Cylinder:
Eyes ≤ 1.0 D²



UDVA:
Eyes $\geq 20/40$ ²



Help deliver the sharp, clear vision your patients need.

"The TRULIGN Toric IOL offers an amazingly stable platform that stays where you place it. Other toric lenses have the tendency to rotate, thereby losing the ability to effectively correct astigmatism. However, in my experience, the TRULIGN Toric IOL rarely ever moves, making it an excellent option not only for patients looking for a broader range of vision, but also for surgeons looking for a great toric lens."

– Farrell "Toby" Tyson, MD, FACS



Innovative design minimizes dysphotopsias.

Advanced features offering exceptional patient outcomes.

Designed to minimize dysphotopsias and potential impact from low light conditions, it's no surprise that 99.2% of patients treated with TRULIGN reported no significant visual disturbances.² Its advanced, aberration-free aspheric optic delivers:

- 100% of light, 100% of the time⁶
- Uniform power, center to edge, for predictable results⁷⁻⁹
- Excellent visual acuity in low light^{1,2}
- Minimized halos and glare²
- Reduced spherical aberration and less sensitivity to decentration²



One complete solution for astigmatic cataract patients.

"Everyone's vision, lifestyle, and expectations are different, which makes it difficult to determine exactly how dependent patients may be on corrective eyewear, even after cataract surgery. However, most of my TRULIGN Toric IOL patients experience a tremendous improvement in their near, intermediate, and distance vision with minimal – if any – dependence on glasses."

– Jeffrey Whitman, MD



TRULIGN Toric delivers long-term vision for your patients and your practice.

TRULIGN Toric IOL offers a **full range of vision,¹ excellent stability,²⁻⁴ and minimized dysphotopias¹** for your patients' life ahead. Combined with leading patient education and practice support programs, TRULIGN Toric can help you achieve outstanding long-term outcomes and continued practice success.

TRULIGN Toric IOL Specifications



Model	TRULIGN Toric IOL BL1UT
Recommended Starting A-constant	119.1*
Recommended Starting ACD	5.61 mm*
Available Now Diopter Power	4.0 to 33.0 D in 0.50 D steps
Cylinder powers – IOL plane	1.25, 2.00, 2.75 D
Cylinder powers – corneal plane	0.83, 1.33, 1.83
Optic body diameter	5.0 mm
Overall diameter	11.5 mm
Material-body and plates	Silicone with UV protection; 10% UV cutoff at 400 nm
Refractive index at 35° C	1.43

*A-constant and ACD are estimates only.
It is recommended that each surgeon develop his or her own values.

TRULIGN.COM

1. TRULIGN Toric IOL Directions for Use. 2. Data on file, Bausch & Lomb Incorporated. Study 650. 3. AcrySof IQ Toric Summary of Safety and Effectiveness Data. 4. AcrySof IQ Toric Directions for Use. 5. Tecnis Toric Directions for Use. 6. Pepose JS, Qazi MA, Davies J, et al. Visual performance of patients with bilateral vs combination Crystalens, ReZoom, and ReSTOR intraocular lens implants. *Am J Ophthalmol.* 2007;144(3):347-357. 7. Santhiago MR, Netto MV, Barreto J Jr, et al. Wavefront analysis, contrast sensitivity, and depth of focus after cataract surgery with aspherical intraocular lens implantation. *Am J Ophthalmol.* 2010;149(3):383-389. 8. Altmann GE, Nichamin LD, Lane SS, Pepose JS. Optical performance of 3 intraocular lens designs in the presence of decentration. *J Cataract Refract Surg.* 2005; 31:574-585. 9. Johansson B, Sundelin S, Wikberg-Matsson A, Unsbo P, Behndig A. Visual and optical performance of the Akreos® Adapt Advanced Optics and Tecnis Z9000 intraocular lenses: Swedish multicenter study. *J Cataract Refract Surg.* 2007;33(9):1565-1572.

INDICATIONS FOR USE: The TRULIGN® toric posterior chamber intraocular lens (IOL) is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia and postoperative refractive astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia who desire reduction of residual refractive cylinder with increased spectacle independence and improved uncorrected near, intermediate and distance vision. **WARNINGS:** Careful preoperative evaluation and sound clinical judgement should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient. Rotation of toric lenses away from their intended axis can reduce their effectiveness, and misalignment can increase postoperative refractive cylinder. The TRULIGN® Toric IOL should only be repositioned when the refractive needs of the patient outweigh the potential risks inherent in any surgical reintervention into the eye. Unlike most other IOLs, the TRULIGN® Toric IOL optic has hinges connecting it to the haptic; please see adverse events section below for more information. **PRECAUTIONS:** The safety and effectiveness of the TRULIGN® Toric intraocular lenses have not been substantiated in patients with preexisting ocular conditions and intraoperative complications. Long-term stability in the human eye has not been established; therefore postoperative monitoring after implant should be performed on a regular basis. Lens rotation less than 5° may not warrant reorientation. Do not sterilize this intraocular lens by any method. Do not store lenses at temperatures over 45°C (113°F). Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the benefit/risk ratio before implanting a lens in a patient with conditions as outlined in the TRULIGN® Toric IOL directions for use. **ADVERSE EVENTS:** The incidence of adverse events experienced during the clinical trial was comparable to or lower than the incidence reported in the historic control ("FDA grid") population. As with any surgical procedure, risk is involved. Vaulting is a post-operative adverse event where the TRULIGN® Toric IOL optic hinges move into and remain in a displaced configuration. If vaulting occurs, please see Directions for Use for a detailed listing of symptoms, information regarding diagnosis, potential causes, and sequelae. Physicians should consider the characteristics of each individual vaulting case prior to determining the appropriate treatment. Data on long-term follow-up after treatment of vaulting is not available. **ATTENTION:** Refer to the Directions for Use labeling for a complete listing of indications, warnings and precautions, clinical trial information, etc. **CAUTION:** Federal (USA) law restricts this device to the sale by or on the order of a physician.



Signature Page for CRT.0020.USA.17 v3.0

Project Manager Approval	Michelle Cook Project Manager 05-Apr-2017 14:41:08 GMT+0000
--------------------------	---

Regulatory Approval	Betty Johnson Regulatory 06-Apr-2017 15:43:55 GMT+0000
---------------------	--

Trademark Approval	Holly Smith Trademark 10-Apr-2017 02:28:06 GMT+0000
--------------------	---

Signature Page for CRT.0020.USA.17 v3.0